Craig Adeyanju

InvestorPlace Contributor

Craig Adeyanju enjoys to unearth awesome growth and value stocks and educate investors about the companies behind them. He believes that the best companies to invest in are those that genuinely solve a problem.

His work has appeared on sites like TheStreet, The Motley Fool, Benzinga among others.

Recent Articles

Yahoo! Inc. Lacks Judgment — Sell YHOO Stock!

By Craig Adeyanju, InvestorPlace Contributor

The operational discipline that helped Yahoo stock reduce expenses doesn’t make up for the fundamental issues. YHOO should be sold.

INTC Stock: Prepare for Major Growth in Intel Corporation’s Mobile Business

By Craig Adeyanju, InvestorPlace Contributor

Intel stock will reportedly supply 50% or more of iPhone 7 modems. This could help INTC improve the profitability of its mobile business.

Wal-Mart Stores, Inc.: Don’t Be Fooled, There’s No Growth With WMT Stock

By Craig Adeyanju, InvestorPlace Contributor

WMT stock is not as much a growth stock as CEO McMillon would have you believe. Don’t even think of buying Walmart if you seek growth.

Apple Inc.: 400 Billion Reasons to Bet on Apple Stock (AAPL)

By Craig Adeyanju, InvestorPlace Contributor

Apple has spent more on auto-related R&D than it's spent on the iPhone. Heck, it's even spent more in incremental R&D than most automakers!

IBB: The iShares NASDAQ Biotechnology Index (ETF) Is Still a Buy

By Craig Adeyanju, InvestorPlace Contributor

Even if Hillary Clinton becomes the next POTUS, biotech stocks won't sink into oblivion -- that's enough reason to buy the IBB ETF.

ABBV Stock: Could AbbVie Inc’s Gamble on Stemcentrx Pay Off?

By Craig Adeyanju, InvestorPlace Contributor

Stemcentrx's acquisition does little to alleviate the risk of the potential decrease in sales once Humira loses patent protection.

Apple Inc.: AAPL Is Losing Its High-End Mojo

By Craig Adeyanju, InvestorPlace Contributor

If Apple can’t find a way to regain its innovative edge and grow the high-end market, AAPL stock will eventually have to target the mass market for growth.

Valeant Pharmaceuticals Intl Inc: Is VRX Stock a Dip-Buying Opportunity?

By Craig Adeyanju, InvestorPlace Contributor

VRX might have finally filed its overdue annual report, but Valeant still faces a long road to recovery.

Sirius XM Holdings Inc. (SIRI): The One Number That Matters

By Craig Adeyanju, InvestorPlace Contributor

Since economical connected cars should become more popular in future, SIRI might become less profitable, as those drivers are less likely to subscribe to Sirius.

McDonald’s Corporation (MCD) Remains on the Road to Recovery

By Craig Adeyanju, InvestorPlace Contributor

MCD has just posted its third consecutive quarter of comparable store sales. It seems a McDonald's recovery is truly on.

Load More